艾媒咨询|2021全球及中国大健康产业运行大数据及决策分析报告

本报告研究涉及企业/品牌/案例：阿里健康，联合丽格，恒瑞医药，白云山，平安好医生，111集团，新氧，药明巨诺，盘龙药业，先导药业，好大夫在线，优健康，春雨医生，丁香医生，微医

受到人口老龄化、居民患病比例增加等因素影响，国家医疗费用支出不断增加，属于刚性需求；同时，随着人们对健康标准的不断提高以及互联网医疗技术的发展，大健康产业会在相当长的时期内持续保持增长态势。数据显示，2020年中国的大健康产业营收规模超过7万亿元，预计2021年将达8万亿元，增幅达8.1%。其中，得益于大健康产业发展以及疫情期间医药需求增长，生物制药、医疗器械两大细分领域表现良好，成为2020年中国投资热度较高的新经济行业，投资项目金额分别为919亿元和273亿元。
Affected by the aging population and the increasing proportion of residents, the national medical expenditure is increasing, which belongs to the rigid demand; At the same time, with the continuous improvement of people's health standards and the development of internet medical technology, the big health industry will continue to grow for a long time. According to the data, the revenue of China's big health industry will exceed 7 trillion yuan in 2020, and it is expected to reach 8 trillion yuan in 2021, an increase of 8.1%. Among them, thanks to the development of big health industry and the growth of pharmaceutical demand during the epidemic period, biopharmaceuticals and medical devices have performed well, becoming China's new economy industry with high investment enthusiasm in 2020, with investment projects of 91.9 billion yuan and 27.3 billion yuan respectively.

艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告

本报告研究涉及企业/品牌/案例：同仁堂、香雪制药、白云山。

数据显示，2020年第三季度，中药材价格指数迎来上涨周期。艾媒咨询分析师认为，受动物类等少数品种拉动影响，预计2020年10-11月中药材指数会持续走高，但是在12月维稳。据调查，绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营，采取减少压货炒作等经营方式。因而，预计中药材市场在2020年末旺季会有一波行情的走高，但随着旺季结束，明年年初的价格会重新回落，随着疫情的常态化，中药材市场行情预期会呈周期性波动的态势。

Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation.

艾媒报告|2019-2021年中国中药材用户调研及延伸市场研究报告

本报告研究涉及企业/品牌/案例：同仁堂，片仔癀，东阿阿胶，太极集团，胡庆余堂，同仁牛黄清心丸，黄芪颗粒，雷氏丹参片，云峰气血口服液，太极五子衍宗丸，太极生力雄丸，仲景左归丸，一笑堂龟甲壳，白云山复方丹参片，天士力养血清脑颗粒，白云山夏桑菊颗粒，白云山板蓝根颗粒

随着居民消费水平的提升和健康保健意识的增强，总体健康需求在扩大，进而推动中医药市场的发展，2018年中国中药材市场规模达1246亿元，同比增长22.40%，预计到2024年，中药材市场规模将达2004亿元。
iiMedia Research（艾媒咨询）调查显示，2019年接近五成受访者购买过中药材，滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛，中医药产业链不断扩展延伸，并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场，建设中药大健康产业，如植物提取物、保健食品、中药化妆品等，已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.

（以下为节选页，完整版共88页）

艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告

本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药

国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。

中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。

Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well.

艾媒报告 |2019全球及中国大健康产业运行大数据及决策分析报告

本报告研究涉及企业/品牌/案例：恒瑞医药，白云山，111集团，平安好医生，好大夫在线，优健康，春雨医生，微医，丁香医生，和美医疗，北大医疗，PHG,新氧，联合丽格，正广兴家庭医生，强森医疗，微脉，美中嘉和，零氪科技，中有精准医疗，思派网络，普瑞眼科，臻和科技，移宇科技，小鹿医馆，妈咪知道，八百方，京东医药，阿里健康大药房，1药网，一心堂，健一网，好药师，健客网，美丽神器，更美，悦美，美莱整形，伊美尔，丽都整形，芝星整形，欧华美科

大健康产业细分领域的垂直深化，推动了大健康产业格局的不断完善。受政策鼓励和资本推动的影响，2019年，大健康产业在患者服务类领域、医疗服务类领域、医药服务类领域、医疗美容类领域和医疗保健类领域等细分场景快速发展。以恒瑞医药、白云山为代表的传统医药上市公司和以平安好医生、111集团和新氧科技为代表的互联网医疗上市企业各自占据大健康产业领域的一席之地。艾媒商情舆情监测系统数据显示，受2018年和2019年上半年医疗领域负面舆情的影响，大健康产业各上市企业正从低谷平稳回升。艾媒咨询分析师认为，受社会医疗需求和国家政策的推动，大健康产业仍是未来投资的亮点。

The vertical deepening of the large health industry segment has promoted the continuous improvement of the pattern of the big health industry. Influenced by policy encouragement and capital promotion, in 2019, the big health industry developed rapidly in the sub-sectors such as patient service, medical services, medical services, medical and beauty, and health care. The traditional pharmaceutical listed companies represented by Hengrui Medicine and Baiyun Mountain and the Internet medical listed companies represented by Ping An Doctor, 111 Group and New Oxygen Technology each occupy a place in the field of large health industry. According to data from the Aibu Business Intelligence Monitoring System, the listed companies in the big health industry are recovering steadily from the bottom of the market due to the negative public sentiment in the medical field in the first half of 2018 and 2019. Ai Media Consulting analysts believe that the health industry is still the highlight of future investment, driven by social medical needs and national policies.

广州白云国际机场股份有限公司2021年第三季度报告

广州白云电器设备股份有限公司2021年第三季度报告